About CoCensys
CoCensys is a Healthcare company based in Irvine (United States) founded in 1989, and was acquired by Purdue Pharma in August 1999. Small molecule therapeutics for CNS disorders were developed. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its competitors include Kriya Therapeutics, Sana Biotechnology and PureTech Health; 3 of its 3 listed competitors have raised funding.
Company details
CoCensys was founded in 1989 in Irvine, United States, and focused on the biotechnology sector for central nervous system disorders. Small molecule therapeutics were developed, including an epalon analog co-developed with Wyeth for anxiety treatment. NMDA receptor antagonists for neuropsychiatric conditions were pursued in partnership with Parke-Davis, and ophthalmic candidates were advanced with Senju Pharma. The company was acquired by Purdue Pharma in 1999 for an undisclosed amount.
- Headquarters Irvine, United States
- Stage Acquired
- SectorsHealthcare
- Website cocensys.com
- Social LinkedIn
- Acquired by Purdue Pharma (Aug 1999)
- Latest Funding Round$750K (USD), Grant
Jun 1999
- InvestorsPurdue Pharma
& 1 more
- Acquired byPurdue Pharma
(Aug 1999)
Funding Insights of CoCensys
- Total Rounds 4
- Last Round Grant — $750,000
- First Round $100,000
(Oct 1997)
- Investors Count 1
All 4 funding rounds of CoCensys with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
2 investors in total: 2 institutional.
Investors in CoCensys
CoCensys has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Purdue Pharma and National Institute of Neurological Disorders and Stroke.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Research on neurological disorders and stroke is conducted and funded. | ninds.nih.gov | Bethesda, United States | ||
Pain-relief drugs are developed by the private pharmaceutical company. | 1892 | purduepharma.com | Stamford, United States |
Investor details for CoCensys
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of CoCensys
4 dated milestones of CoCensys across 10 years, from founding to its latest funding, stage changes and deals.
- Founded CoCensys is founded.
- Funding First funding round of $100K.
- Funding Latest funding round, Grant, of $750K.
- Exit Acquired by Purdue Pharma.
Competitors of CoCensys
CoCensys has 3 listed competitors in our database, 3 of them funded. They include Kriya Therapeutics, Sana Biotechnology and PureTech Health.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| kriyatherapeutics.com | 2012 | Redwood, United States | $930.93M | 159 | Developer of therapeutic solutions for the treatment of diabetes | |
| sana.com | 2018 | Seattle, United States | $821M | 328 | Genetically engineered cell therapies are developed for multiple disorders. | |
| puretechhealth.com | 2001 | Boston, United States | $107M | 171 | Immunotherapeutics are developed for inflammation, fibrosis, and lung diseases. |
Detailed competitors of CoCensys
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Neurology
3 companies that operate in the same segment as CoCensys (Neurology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed. | 2013 | San Francisco, California, United States | USD 214.78 M | USD 21.05 M | 211 | |
Developer of therapeutics for psychiatric and neurologic diseases | 2002 | New York, New York, United States | USD 80.87 M | USD 250.31 M | 600 | |
Biologics platform developed for intracellular delivery in rare diseases. | 2016 | Boston, Massachusetts, United States | USD 175.25 M | USD 25.42 M | 183 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about CoCensys
CoCensys was founded in 1989 and raised its 1st funding round 8 years after it was founded.
CoCensys is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
CoCensys was founded in 1989 in Irvine, United States, and focused on the biotechnology sector for central nervous system disorders. Small molecule therapeutics were developed, including an epalon analog co-developed with Wyeth for anxiety treatment. NMDA receptor antagonists for neuropsychiatric conditions were pursued in partnership with Parke-Davis, and ophthalmic candidates were advanced with Senju Pharma. The company was acquired by Purdue Pharma in 1999 for an undisclosed amount.
CoCensys's top competitors include Sana Biotechnology, PureTech Health and Kriya Therapeutics.
CoCensys has 2 investors. Key investors include Purdue Pharma, and National Institute of Neurological Disorders and Stroke.
Yes. CoCensys was acquired by Purdue Pharma in August 1999.